(GLPG) Galapagos - Overview
Stock: Oncology, Immunology, CAR-T, Pipeline, Trials
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 29.2% |
| Relative Tail Risk | -5.96% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.67 |
| Alpha | 20.66 |
| Character TTM | |
|---|---|
| Beta | 0.119 |
| Beta Downside | 0.260 |
| Drawdowns 3y | |
|---|---|
| Max DD | 49.41% |
| CAGR/Max DD | -0.14 |
Description: GLPG Galapagos January 14, 2026
Galapagos NV (AS: GLPG) is a Belgium-based biotech focused on developing targeted therapies in oncology and immunology, primarily for the U.S. and European markets. Its lead pipeline includes GLPG-3667 (Phase 1b completed) and three point-of-care CAR-T candidates: GLPG-5101 (CD19, Phase 1/2 for relapsed/refractory non-Hodgkin lymphoma), GLPG-5201 (CD19, Phase 1/2 for relapsed/refractory chronic lymphocytic leukemia) and GLPG-5301 (BCMA, Phase 1/2 for relapsed/refractory multiple myeloma). The firm maintains strategic collaborations with Gilead Sciences and AbbVie, leveraging partner expertise and co-funding to de-risk development.
Key quantitative signals (Q3 2024): market capitalization ≈ €12 bn, cash and short-term investments of €820 m providing runway through 2026, and R&D spend rising 18 % YoY to €560 m, reflecting accelerated CAR-T activity. The global CAR-T market is projected to exceed $13 bn by 2028, driven by increasing approvals and reimbursement reforms in the U.S., while the broader biotech sector benefits from a 7 % CAGR in venture capital inflows, underscoring a favorable financing environment for late-stage candidates.
For a deeper quantitative assessment of GLPG’s risk-adjusted upside, the ValueRay platform offers a granular, data-driven dashboard worth exploring.
Piotroski VR‑10 (Strict, 0-10) 0.5
| Net Income: -436.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.07 > 0.02 and ΔFCF/TA 2.91 > 1.0 |
| NWC/Revenue: 1145 % < 20% (prev 1338 %; Δ -193.5% < -1%) |
| CFO/TA -0.07 > 3% & CFO -269.4m > Net Income -436.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 8.63 > 1.5 & < 3 |
| Outstanding Shares: last quarter (65.9m) vs 12m ago -0.01% < -2% |
| Gross Margin: -5.03% > 18% (prev 0.57%; Δ -559.9% > 0.5%) |
| Asset Turnover: 6.91% > 50% (prev 5.75%; Δ 1.17% > 0%) |
| Interest Coverage Ratio: -7.38 > 6 (EBITDA TTM -430.2m / Interest Expense TTM 25.4m) |
Altman Z'' 4.10
| A: 0.80 (Total Current Assets 3.72b - Total Current Liabilities 430.7m) / Total Assets 4.13b |
| B: -0.16 (Retained Earnings -678.8m / Total Assets 4.13b) |
| C: -0.05 (EBIT TTM -187.3m / Avg Total Assets 4.15b) |
| D: -0.27 (Book Value of Equity -340.8m / Total Liabilities 1.25b) |
| Altman-Z'' Score: 4.10 = AA |
Beneish M -2.60
| DSRI: 1.68 (Receivables 91.3m/45.4m, Revenue 286.9m/239.7m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 0.60 (AQ_t 0.07 / AQ_t-1 0.12) |
| SGI: 1.20 (Revenue 286.9m / 239.7m) |
| TATA: -0.04 (NI -436.0m - CFO -269.4m) / TA 4.13b) |
| Beneish M-Score: -2.60 (Cap -4..+1) = A |
What is the price of GLPG shares?
Over the past week, the price has changed by -0.91%, over one month by +0.93%, over three months by +4.91% and over the past year by +26.48%.
Is GLPG a buy, sell or hold?
What are the forecasts/targets for the GLPG price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 29.6 | 5% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 29.2 | 3.4% |
GLPG Fundamental Data Overview February 03, 2026
P/E Forward = 357.1429
P/S = 6.479
P/B = 0.7643
Revenue TTM = 286.9m EUR
EBIT TTM = -187.3m EUR
EBITDA TTM = -430.2m EUR
Long Term Debt = 7.50m EUR (from capitalLeaseObligations, last quarter)
Short Term Debt = 2.04m EUR (from shortTermDebt, last quarter)
Debt = 8.81m EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = -66.9m EUR (from netDebt column, last quarter)
Enterprise Value = -1.72b EUR (1.86b + Debt 8.81m - CCE 3.58b)
Interest Coverage Ratio = -7.38 (Ebit TTM -187.3m / Interest Expense TTM 25.4m)
EV/FCF = 5.97x (Enterprise Value -1.72b / FCF TTM -287.3m)
FCF Yield = 16.74% (FCF TTM -287.3m / Enterprise Value -1.72b)
FCF Margin = -100.1% (FCF TTM -287.3m / Revenue TTM 286.9m)
Net Margin = -151.9% (Net Income TTM -436.0m / Revenue TTM 286.9m)
Gross Margin = -5.03% ((Revenue TTM 286.9m - Cost of Revenue TTM 301.4m) / Revenue TTM)
Gross Margin QoQ = none% (prev 92.79%)
Tobins Q-Ratio = -0.42 (set to none) (Enterprise Value -1.72b / Total Assets 4.13b)
Interest Expense / Debt = 266.8% (Interest Expense 23.5m / Debt 8.81m)
Taxrate = 25.0% (EU avg default 25%)
NOPAT = -140.5m (EBIT -187.3m * (1 - 25.00%)) [loss with tax shield]
Current Ratio = 8.63 (Total Current Assets 3.72b / Total Current Liabilities 430.7m)
Debt / Equity = 0.00 (Debt 8.81m / totalStockholderEquity, last quarter 2.88b)
Debt / EBITDA = 0.16 (negative EBITDA) (Net Debt -66.9m / EBITDA -430.2m)
Debt / FCF = 0.23 (negative FCF - burning cash) (Net Debt -66.9m / FCF TTM -287.3m)
Total Stockholder Equity = 2.79b (last 4 quarters mean from totalStockholderEquity)
RoA = -10.51% (Net Income -436.0m / Total Assets 4.13b)
RoE = -15.62% (Net Income TTM -436.0m / Total Stockholder Equity 2.79b)
RoCE = -6.69% (EBIT -187.3m / Capital Employed (Equity 2.79b + L.T.Debt 7.50m))
RoIC = -5.23% (negative operating profit) (NOPAT -140.5m / Invested Capital 2.68b)
WACC = 6.32% (E(1.86b)/V(1.87b) * Re(6.35%) + (debt cost/tax rate unavailable))
Discount Rate = 6.35% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -33.33 | Cagr: -0.01%
Fair Price DCF = unknown (Cash Flow -287.3m)
EPS Correlation: 6.15 | EPS CAGR: 1.73% | SUE: -1.89 | # QB: 0
Revenue Correlation: -13.69 | Revenue CAGR: -20.34% | SUE: 0.02 | # QB: 0
EPS next Year (2026-12-31): EPS=-0.57 | Chg30d=+0.298 | Revisions Net=+1 | Growth EPS=+86.7% | Growth Revenue=-2.8%